Mineralys Therapeutics (MLYS) announced that it has commenced an underwritten public offering of $175M of shares of its common stock. All of the securities to be sold in the offering are to be sold by Mineralys. Mineralys intends to use the net proceeds from the proposed offering to fund clinical development of lorundrostat, including research and development and manufacturing, and pre-commercialization activities, as well as for working capital and general corporate purposes. BofA Securities, Evercore ISI, Goldman Sachs & Co., Stifel and Wells Fargo Securities are acting as joint book-running managers for the offering. LifeSci Capital is acting as lead manager and H.C. Wainwright & Co. is acting as co-manager for the offering.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MLYS:
- 3 Best Stocks to Buy Now, 9/2/2025, According to Top Analysts
- Jefferies expects Mineralys stock to trade up following AstraZeneca data
- Buy Rating for Mineralys Therapeutics Driven by Competitive Position and Strategic Milestones
- Mineralys Therapeutics, Inc. Earnings Call Highlights
- Mineralys Therapeutics price target raised to $43 from $38 at BofA